The Company's board of directors re-elected
Dr. Chan Chi-Hsien as the chairperson
Date of events
2022/06/29
To which item it meets
paragraph 6
Statement
1.Date of the board of directors resolution or date of occurrence of the
change:2022/06/29
2.Position (Please enter chairperson or president/general manager):
Chairperson
3.Name of the previous position holder:Chan, Chi Hsien
4.Resume of the previous position holder:Chairman, Adimmune Corporation
5.Name of the new position holder:Chan, Chi Hsien
6.Resume of the new position holder:Chairman, Adimmune Corporation
7.Circumstances of change (Please enter "resignation", "dismissal",
"term expired" , "job relocation", "severance", "retirement",
"death" or "new appointment"):Term expired
8.Reason for the change:Re-election of directors
9.Effective date of the new appointment:2022/06/29
10.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Adimmune Corporation published this content on 29 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 June 2022 05:46:10 UTC.
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.